n n n ‘. concat(e. i18n. t(“search. voice. recognition_retry”),’n
GAITHERSBURG, Md., Dec. 20, 2023 /PRNewswire/ — YS Biopharma Co., Ltd. (NASDAQ: YS) (“YS Biopharma” or the “Company”), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today issues an official response to the unauthorized press release disseminated under our name. We take this matter with utmost seriousness and wish to clarify the following points:
Mr. Yi Zhang’s Chairman: Our filing on Form 6-K with the U. S. Securities and Exchange CommissionThe U. S. Charter, on December 12, 2023, explicitly discloses the existing composition of our Board of Directors (the “Board”), and Mr. Yi Zhang is the Chairman of our Board. As a result, Mr. Zhang has no authority to call a general meeting of the Company’s shareholders.
Extraordinary General Meeting: Dr. Ajit Shetty, the last interim Chairman of the Board of Directors, has not convened an Extraordinary General Meeting of the Company to be held on December 28, 2023. Any communication you suggest differently is misleading and unauthorized. Shareholders are invited to the ordinary general meeting supposedly published under our call and circulated through PRNewswire. The assembly in question is not sanctioned by the Corporation and its presence is not necessary.
YS Biopharma encourages all interested parties to seek accurate data on the company’s official communication channels and to refrain from acting on the basis of unauthorized statements.
About YS Biopharma
YS Biopharma is a global biopharmaceutical corporation committed to the discovery, development, production, and commercialization of next-generation curative vaccines and biologics for infectious diseases and cancer. It has developed a proprietary PIKA® immunomodulator generation platform and a number of preventive and curative biologics that may only be vaccines against rabies, coronavirus, hepatitis B, influenza, and shingles. YS Biopharma operates in China, the United States, Singapore and the Philippines and is led by a control team that combines rich local expertise and global expertise in the biopharmaceutical sector. industry. For more information, visit invest. ysbiopharm. com.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains ”forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical or current fact included in this press release are forward-looking statements, including but not limited to statements regarding the expected growth of YS Biopharma, the development progress of all product candidates, the progress and results of all clinical trials, YS Biopharma’s ability to source and retain talent, and the cash position of YS Biopharma following the closing of the Business Combination. Forward-looking statements may be identified by the use of words such as “estimate,” “plan,” “project,” “forecast,” “intend,” “will,” “expect,” “anticipate,” “believe,” “seek,” “target” or other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These statements are based on various assumptions, whether or not identified in this press release, and on the current expectations of YS Biopharma’s management and are not predictions of actual performance.
These involve dangers, uncertainties and other points that would possibly cause actual effects, degrees of activity, functionality or achievements to differ materially from those expressed or implied by such forward-looking announcements. Although YS Biopharma believes it has a moderate basis for each of the forward-looking statements contained in this press release, YS Biopharma cautions that those announcements are based on a combination of recently known facts and points and long-term projections, which are inherently uncertain. In addition, there are dangers and uncertainties that are described in the latest release. prospectus related to the proposed business combination and in other documents filed through YS Biopharma from time to time with the SEC. These documents would possibly identify and address other vital hazards and uncertainties that may also cause actual events and effects to differ materially from those contained in the document.
YS Biopharma cannot assure you that the forward-looking statements contained in this press release will prove to be accurate. These forward-looking statements are subject to a number of threats and uncertainties, including, among others, the ability to recognize the expected benefits of the business combination, the prices associated with the transaction, the effect of the global COVID pandemic. -19, the threat that the transaction will disrupt existing plans and operations due to the consummation of the transaction, the latest results of any potential litigation, any governmental or regulatory proceedings, the advertising functionality of the announced vaccine product and the effects of progression from the YS clinical trial. Biopharma’s product candidates and other threats and uncertainties, including those included under the heading “Risk Factors” in the final prospectus filed with the SEC on February 8, 2023, completed on February 21, 2023, and in other filings of the SEC. There may be other threats that YS Biopharma is not aware of or that YS Biopharma considers irrelevant, which could also cause actual effects to differ from those contained in the forward-looking statements. In light of the significant uncertainties related to such forward-looking statements, nothing in this press release should be construed as a representation by any user that the forward-looking statements set forth herein will become known or that any of the weighted effects of such Forward-looking statements: attractive statements will result. The forward-looking statements contained in this press release constitute YS Biopharma’s views as of the date of this press release. Subsequent events and progressions would likely supersede those perspectives. However, although YS Biopharma may update such forward-looking statements in the future, there is no intention to do so unless required by applicable law. Therefore, you should not rely on such forward-looking statements as constituting YS Biopharma’s views as of any date subsequent to the date of this press release. Except as required by law, YS Biopharma undertakes no legal responsibility to update such forward-looking statements.
Investor Relations ContactsRobin YangPartner, ICR, LLCTel: 1 (212) 537-4035Email: YSBiopharma. IR@icrinc. com
View original content to download multimedia:https://www.prnewswire.com/news-releases/ys-biopharma-responds-to-unauthorized-press-release-regarding-extraordinary-general-meeting-302020366.html
SOURCE YS Biopharma Co. , Ltd.